Use access key #2 to skip to page content.
  • S&P 500: 1,070.52
  • Change: 1.30%
$6.94 0.07 (1.02%)
2/9/2010 4:00 PM

Allos Therapeutics, Inc. (ALTH)

CAPS Rating:
*****

A biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating ALTH

Add Stock to Watchlist

What the Community Thinks

Total Members

259 Outperforms
14 Underperforms
 

All-Stars

81 Outperforms
5 Underperforms
 

Wall Street

14 Outperforms
0 Underperforms
 

Members bullish on ALTH are also bullish on:

Members bearish on ALTH are also bearish on:

Ticker Tags

Aggressive Growth (860), Biotechnology (220), Healthcare (711), Bio-Pharmaceuticals (29), Growth (1902), Defensive (1457), Small Cap (1645)
Suggest a tag

Allos Therapeutics, Inc. At A Glance

Current Price: $6.94
Last Trade Time: 2/9/2010 4:00 PM
Open: $6.94
Previous Close: $6.87
Daily Range: $6.84 - $7.03
52-Week Range: $5.34 - $8.79
Volume: 422,737
Market Cap: $721.35M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

ALTH VS S&P 500 (SPY)

News & Discussion Boards

Top Bull Pitch

Recs

1

Allos Therapeutics, Inc. (ALTH)

Avatar codergrrl (23.72) Submitted: 1/07/08 4:49 PM

Allos Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule therapeutics for the treatment of cancer.

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

5

Allos Therapeutics, Inc. (ALTH)

Avatar Ruthie203 (25.92) Submitted: 2/15/08 11:07 AM

Wow, I just can't see it. With constant new management, directors, increased stock options, no viable product, living off investor money with promises that FDA might approve 2 bios, seems too risky for me. I might go it if not for the exit of 2 directors and future of another issuance of stock.

Replies: 0 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 37 :   1 2 3 4 5 Next »

Recs

0

 (ALTH)

Avatar randomvariable (99.27) Submitted: 2/02/10 10:35 AM : Outperform Start Price: $6.98 ALTH Score: -0.52

Cashed out some points on Allos already, but if they move further along the FDA process, their value could go up substantially. Note the "if" and "could." Currently $7.34, setting a limit buy of $7.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ALTH)

Avatar Biotech2010 (40.47) Submitted: 1/26/10 8:50 PM : Outperform Start Price: $7.18 ALTH Score: -1.56

@6.58

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ALTH)

Avatar tctk1044 (72.53) Submitted: 1/22/10 10:53 AM : Outperform Start Price: $7.82 ALTH Score: -7.54

Major purchase option for a larger pharmaceutical company. Over the past year this company has stabalized itself significantly. FOLOTYN already has approval through the FDA for use in some cancers, and its market will only grow as the drug gains approval for other uses.

Noting that FOLOTYN is already approved for some use makes this a secure biopharm to bet on. Knowing that the drug is in late-stage trials for use in the treatment of other cancers makes this a better bet. Knowing that it will be a one of a kind and most likely will beat all others to market with this kind of drug makes this a great bet. And watching big pharma companies salivate as they wait for the next couple of trials finalize (does anyone else hear the buyout bell ringing?) makes this a great bet for the next 12-24 months.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ALTH)

Avatar 927jillian (< 20) Submitted: 12/30/09 12:47 PM : Outperform Start Price: $6.52 ALTH Score: 11.05

as research becomes more advance, the % of tumor reduction will increase, soon:and with the new health care bill, health providers will be obligated to use the drug. Then you have Europe...all good:

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ALTH)

Avatar ebitdat (66.57) Submitted: 12/22/09 9:07 PM : Outperform Start Price: $6.30 ALTH Score: 14.43

It's drug will be a huge money-maker and has the potential to treat several other rare cancers.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 37 :   1 2 3 4 5 Next »

Wall Street

Results 1 - 14 of 14  

picks per page. CHANGE Expand All Pitches

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackThinkEquity 64.82 11/24/09 Outperform NS $6.26+10.86%-3.41%+14.27
TrackLeerinkSwan 92.83 07/14/09 Outperform NS $7.56-8.20%+19.20%-27.40
TrackJimCramer < 20 02/27/09 Outperform 3W $5.64+23.05%+47.58%-24.53
TrackWellsFargo 80.02 12/04/08 Outperform NS $6.01+15.47%+27.82%-12.35
TrackCitigroup 85.92 06/26/08 Outperform NS $6.49+6.93%-15.27%+22.20
TrackMichaelBrus 92.73 02/14/08 Outperform 1Y $6.75+2.81%-17.33%+20.15
TrackBofASec 94.61 12/04/07 Outperform NS $7.26-4.41%-23.41%+19.00
TrackCollinsStew 68.03 11/08/07 Outperform NS $5.90+17.63%-23.88%+41.51
TrackSoros 82.58 09/30/07 Outperform NS $4.75+46.11%-26.38%+72.48 Toggle the visibility of 60-Second Pitch and replies
TrackRBCCapMkts 86.33 06/20/07 Outperform NS $5.54+25.27%-26.18%+51.45
TrackRodmanRen < 20 12/08/06 Outperform NS $7.13-2.65%-19.35%+16.70
TrackJMP 71.98 12/07/06 Outperform NS $7.15-2.94%-19.95%+17.01
TrackMDB < 20 10/11/06 Outperform NS $3.92+77.04%-15.60%+92.64
TrackNeedham 67.64 09/05/06 Outperform NS $4.16+66.83%-13.08%+79.91

Results 1 - 14 of 14  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners

EQWEBD02 281ms